April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Recombinant Membrane-Targeted CD59 Inhibits the Growth of Choroidal Neovascular Complex in Murine Model of Laser-Induced Choroidal Neovascularization (CNV)
Author Affiliations & Notes
  • J. Liu
    Ophthal/Microbiol & Immunol,
    Univ of Arkansas for Med Sciences, Little Rock, Arkansas
  • P. Jha
    Ophthalmology, Jones Eye Institute - UAMS, Little Rock, Arkansas
  • V. V. Lyzogubov
    Ophthalmology, Jones Eye Institute - UAMS, Little Rock, Arkansas
  • P. S. Bora
    Ophthalmology/Jones Eye Institute, Univ of Arkansas for Med Sci, Little Rock, Arkansas
  • N. S. Bora
    Ophthal, Jones Eye Inst,
    Univ of Arkansas for Med Sciences, Little Rock, Arkansas
  • Footnotes
    Commercial Relationships  J. Liu, None; P. Jha, None; V.V. Lyzogubov, None; P.S. Bora, None; N.S. Bora, None.
  • Footnotes
    Support  This work was supported by NIH grants EY016205 & EY 014623 and Pat & Willard Walker Eye Research Center, Jones Eye Institute, Little Rock, AR.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 405. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Liu, P. Jha, V. V. Lyzogubov, P. S. Bora, N. S. Bora; Recombinant Membrane-Targeted CD59 Inhibits the Growth of Choroidal Neovascular Complex in Murine Model of Laser-Induced Choroidal Neovascularization (CNV). Invest. Ophthalmol. Vis. Sci. 2010;51(13):405. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : This study was designed to explore the effect of recombinant, membrane targeted CD59 (rCD59-APT542) on the growth as well on the size of fully developed neo-vascular complex using the murine model of laser-induced choroidal neovascularization (CNV).

Methods: : Argon laser photocoagulation was used to induce CNV in C57BL/6 mice. After laser treatment, animals received i.p. or subretinal injection of rCD59-APT542 at day 3 (during the growth of CNV) and sacrificed at day 7 post-laser. Another group of animals received i.p. (days 7 and 9 post-laser) or subretinal (day 7 post-laser) injection of rCD59-APT542 and sacrificed at day 12 post-laser (fully developed CNV). The presence of rCD59-APT542 in mouse RPE-choroid was analyzed using Western blot analysis. The incidence as well as the size of CNV complex was determined using flat mounted RPE-choroid-sclera, confocal microscopy and ImageJ program. MAC deposition in RPE-choroid was evaluated by immunohistochemistry.

Results: : Western blot analysis demonstrated that a single i.p. injection of rCD59-APT542 delivers the protein to the RPE-choroid and the protein is retained in these tissues for up to 5 days. MAC analysis revealed that exogenously administered rCD59-APT542 is functionally active in the RPE-choroid. Administration of rCD59-APT542 at day 3 post-laser resulted in ~ 74% (i.p. injection) and ~ 79% (subretinal injection) inhibition of the further growth of CNV complex compared to similar treatment with sterile PBS. Our results further demonstrated that treatment with rCD59-APT542 at days 7 and 9 post-laser also resulted in ~ 42% (i.p. injection) inhibition of the CNV complex in C57BL/6 mice compared to PBS injected control animals. A single subretinal injection of rCD59-APT542 at day 7 inhibited the CNV complex by ~ 44%.

Conclusions: : Our results demonstrate that rCD59-APT542 inhibits the growth of CNV complex as well as the size of fully developed CNV in the laser-induced mouse model. We believe that membrane targeted CD59 may have therapeutic potential in humans since our present study mimics the frequent clinical presentation of AMD in humans.

Keywords: age-related macular degeneration • choroid: neovascularization • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×